This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Hikma Pharmaceuticals (HKMPF) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Hikma Pharmaceuticals (HKMPF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Hikma Pharmaceuticals Plc (HKMPF) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Hikma Pharmaceuticals Plc (HKMPF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why "Trend" Investors Would Love Betting on Hikma Pharmaceuticals Plc (HKMPF)
by Zacks Equity Research
Hikma Pharmaceuticals Plc (HKMPF) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Pacira (PCRX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Pacira (PCRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Rigel Pharmaceuticals (RIGL) Looks Good: Stock Adds 9.7% in Session
by Zacks Equity Research
Rigel Pharmaceuticals (RIGL) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
HKMPF vs. NBIX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HKMPF vs. NBIX: Which Stock Is the Better Value Option?
Lannett (LCI) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Lannett (LCI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
HKMPF or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HKMPF vs. ZTS: Which Stock Is the Better Value Option?
Ironwood Commences Phase I Study on IW-6463 for CNS Disorders
by Zacks Equity Research
Ironwood (IRWD) begins a phase I study on CNS-penetrant soluble guanylate cyclase stimulator, IW-6463, for treating severe CNS disorders.
Ocular (OCUL) Submits an sNDA for Eye Pain Drug Dextenza
by Zacks Equity Research
Ocular (OCUL) files an sNDA to the FDA for expanding the label of its eye drug, Dextenza, to treat ocular inflammation post ophthalmic surgery.
Karyopharm Files MAA for Myeloma Candidate Selinexor in EU
by Zacks Equity Research
Karyopharm (KPTI) tenders a marketing application to European regulatory authority with the purpose of seeking an approval for selinexor to address patients with penta-refractory multiple myeloma.
Neurocrine Gives Ingrezza Sales View, Updates on Pipeline
by Zacks Equity Research
Neurocrine (NBIX) issues preliminary sales outlook for Ingrezza with respect to the fourth quarter of 2018 as well as the full year. The company also lends an update on its pipeline.
Spectrum Pharma Fully Enrolls 1St Cohort in Poziotinib Study
by Zacks Equity Research
Spectrum Pharma (SPPI) completes enrollment in the first cohort of a phase II study on poziotinib for previously treated NSCLC patients with EGFR exon 20 insertion mutations. Shares rise.
Flexion Starts Phase III Enrollment on Zilretta for Hip OA
by Zacks Equity Research
Flexion (FLXN) initiates enrollment in phase III study on its pain drug, Zilretta, for the treatment of patients suffering hip osteoarthritis.
Spectrum Pharma Files BLA for Neutropenia Candidate Rolontis
by Zacks Equity Research
Spectrum Pharma (SPPI) petitions for a BLA to the FDA regarding its lead pipeline candidate, Rolontis, to address chemotherapy-induced neutropenia in patients with breast cancer.
Small Drug Stocks Near-Term Outlook Positive, Despite Headwinds
by Zacks Equity Research
Small drugmakers, in general, are having a decent year, despite failures of key pipeline candidates in pivotal studies.
Portola (PTLA) Down as CHMP Defers Review Date for Ondexxya
by Zacks Equity Research
The CHMP postpones the review timeline of Portola's (PTLA) Ondexxya (in the EU. Shares take a hit.
Jazz (JAZZ) Increases Share Buyback Authorization by $400M
by Zacks Equity Research
Jazz's (JAZZ) board sanctions a raise in its share buyback authorization by $400 million.
Theravance's Respiratory Disease JAK Inhibitor Enters Phase I
by Zacks Equity Research
Theravance (TBPH) doses the first patient in a phase I study on novel JAK inhibitor, TD-8236, for treating serious respiratory diseases.
Theravance JAK Inhibitor Enters Phase II for Crohn's Disease
by Zacks Equity Research
Theravance (TBPH) doses the first patient in a phase II Crohn's disease study on JAK inhibitor, TD-1473.
U.K. Economy Grows at Fastest Pace in Nearly a Year: 5 Picks
by Swarup Gupta
The football World Cup and unexpectedly warm weather led to a pickup in consumer spending.
New Strong Sell Stocks for February 9th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for July 27th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Aclaris Therapeutics (ACRS) Worth a Look: Stock Rises 8.5%
by Zacks Equity Research
Aclaris Therapeutics, Inc. (ACRS) shares rose over 8% in the last trading session.
Avadel Pharmaceuticals (AVDL) Looks Good: Stock Up 5.3%
by Zacks Equity Research
Avadel Pharmaceuticals plc (AVDL) shares rose over 5% in the last trading session.